Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | SI | P14410 | 2/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 5/20 | 0.35 |
| ▸ | CCR7 | P32248 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487312 | 0.86 | HPGD (0.39) | TOP2AMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL490032 | 0.86 | CXCR2 (0.47) | MEN1KMT2AMGAMGAASI | |
| SCHEMBL27714932 | 0.83 | KMT2A (0.40) | KMT2AMAPTNPSR1HTTL3MBTL1 | |
| SCHEMBL1487220 | 0.81 | CXCR2 (0.38) | TOP2AMGAMGAASIMGAM2 | |
| SCHEMBL490197 | 0.79 | CXCR2 (0.49) | TOP2AMEN1KMT2AMAPTMGAM | |
| SCHEMBL489678 | 0.77 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2MGAMGAA | |
| SCHEMBL490008 | 0.77 | NPC1 (0.48) | MEN1KMT2ASMN1; SMN2CXCR2CCR7 | |
| SCHEMBL490121 | 0.75 | KDM1A (0.38) | TOP2AMEN1KMT2AMAPTMGAM | |
| SCHEMBL1487070 | 0.75 | CXCR2 (0.43) | MEN1KMT2AMGAMGAASI | |
| SCHEMBL28010880 | 0.75 | KMT2A (0.50) | MEN1KMT2AMAPTSMN1; SMN2CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102796081-B | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB | 2015-04-22 | — | — | CN | disclosed |
| US-8722883-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2014-05-13 | — | — | US | disclosed |
| EP-1809624-B1 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2013-11-20 | — | — | EP | disclosed |
| US-20130203991-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA R&D ALDERLY PARK (GB) | 2013-08-08 | — | — | US | disclosed |
| US-8410123-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2013-04-02 | — | — | US | disclosed |
| US-20130012490-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2013-01-10 | — | — | US | disclosed |
| US-8269002-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| US-20120157431-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2012-06-21 | — | — | US | disclosed |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| EP-2311827-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators. | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301933-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-7838675-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2010-11-23 | — | — | US | disclosed |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157431-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | TOP2A 1534/4885MEN1 4811/4885KMT2A 4551/4885 |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | TOP2A 1534/4885MEN1 4811/4885KMT2A 4551/4885 |
| US-20130203991-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | TOP2A 1534/4885MEN1 4811/4885KMT2A 4551/4885 |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | TOP2A 1656/4885MEN1 4783/4885KMT2A 4526/4885 |
| US-20130012490-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | TOP2A 1656/4885MEN1 4783/4885KMT2A 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.